Details of the Drug Pharmacogenomic Perturbation Atlas

Dipyridamole Drug Info

Agilease; Anginal; Antistenocardin; Apricor; Cardioflux; Cardoxil; Cardoxin; Cerebrovase; Chilcolan; Cleridium; Coribon; Coridil; Coronarine; Corosan; Coroxin; Curantil; Curantyl; Dipiridamol; Dipyramidole; Dipyridamine; Dipyridamol; Dipyridamolum; Dipyridan; Dipyudamine; Dypyridamol; Gulliostin; Justpertin; Kurantil; Miosen; Natyl; Peridamol; Permiltin; Persantin; Persantine; Piroan; Prandiol; Protangix; Stenocardil; Stenocardiol; Stimolcardio; Apotex Brand of Dipyridamole; Ashbourne Brand of Dipyridamole; Belmac Brand of Dipyridamole; Berlin Chemie Brand of Dipyridamole; Boehringer Ingelheim Brand of Dipyridamole; IPRAD Brand of Dipyridamole; Iv Persantine; Novopharm Brand of Dipyridamole; Cleridium 150; D 9766; Prandiol 75; Apo-Dipyridamole; Apo-Dipyridamole Fc; Apo-Dipyridamole Sc; Berlin-Chemie Brand of Dipyridamole; Dipiridamol [INN-Spanish]; Dipyridamolum [INN-Latin]; Novo-Dipiradol; Persantine (TN); RA-8; Usaf Ge-12; Dipyridamole (JP15/USP/INN); Dipyridamole [USAN:INN:BAN:JAN]; Permole, Persantine, Dipyridan, Dipyridamole; 2,6-Bis(diethanolamine)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido(5,4-d)pyrimidine; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine

Therapeutic Class

Vasodilator Agents

Cross-matching ID

PubChem CID

3108

ChEBI ID

CHEMBL932

CAS Number

CAS 58-32-2

TTD Drug ID

D0F9GE

VARIDT Drug ID

DR00613

INTEDE Drug ID

DR2282

ACDINA Drug ID

D00204

General Information of Drug (ID: DMXY30O)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
DNA replication	2.31	0.00e+0	34/36 (94.44%)	POLE2;PRIM1;FEN1;...
Cell cycle	2.01	2.67e-3	110/124 (88.71%)	CDC20;CDKN2C;PLK1;...
Fanconi anemia pathway	1.92	1.78e-3	36/54 (66.67%)	FANCG;FANCI;RPA3;...
Porphyrin and chlorophyll metabolism	1.87	5.35e-3	23/43 (53.49%)	UGT2B15;UGT2B17;GUSB;...
Parkinson disease	1.84	1.07e-2	176/249 (70.68%)	PPIF;CYCS;CALML5;...
Base excision repair	1.81	1.34e-2	29/33 (87.88%)	POLE2;FEN1;PCNA;...
Oxidative phosphorylation	1.80	1.22e-2	93/133 (69.92%)	NDUFB8;SDHD;ATP5MG;...
Caffeine metabolism	1.70	2.41e-2	5/6 (83.33%)	NAT1;NAT2;CYP1A2
Homologous recombination	1.66	4.28e-2	35/41 (85.37%)	RPA3;BRCA1;MRE11;...
Mineral absorption	1.65	3.96e-2	48/60 (80%)	SLC30A1;MT1E;MT1H;...
Thermogenesis	1.62	4.96e-2	173/232 (74.57%)	MGLL;FGFR1;NDUFB8;...
Proteasome	1.61	4.86e-2	44/46 (95.65%)	PSMD2;PSMC3;PSMD11;...
Oocyte meiosis	1.61	4.69e-2	90/129 (69.77%)	CDC20;PLK1;CCNB1;...
Pentose phosphate pathway	-1.70	2.16e-2	25/30 (83.33%)	H6PD;PGM1;TALDO1;...
Epstein-Barr virus infection	-1.70	2.10e-2	189/202 (93.56%)	MAPK14;IRF9;SNW1;...
Kaposi sarcoma-associated herpesvirus infection	-1.70	2.17e-2	172/193 (89.12%)	MAPK14;JAK2;IRF9;...
Toll-like receptor signaling pathway	-1.73	1.99e-2	94/104 (90.38%)	TAB1;TLR4;AKT2;...
AGE-RAGE signaling pathway in diabetic complications	-1.75	1.79e-2	97/100 (97%)	IL1B;COL4A6;PLCG2;...
C-type lectin receptor signaling pathway	-1.77	1.53e-2	93/104 (89.42%)	AKT2;MAPK1;PYCARD;...
Asthma	-1.78	1.59e-2	25/31 (80.65%)	EPX;HLA-DRA;TNF;...
Shigellosis	-1.78	1.66e-2	180/246 (73.17%)	GABARAPL2;ACTN4;HK2;...
Fc gamma R-mediated phagocytosis	-1.79	1.61e-2	79/97 (81.44%)	PIK3CA;MYO10;ACTR2;...
Inflammatory bowel disease	-1.80	1.62e-2	58/65 (89.23%)	TBX21;TGFB1;HLA-DPB1;...
PD-L1 expression and PD-1 checkpoint pathway in cancer	-1.82	1.34e-2	79/89 (88.76%)	PLCG1;MAPK3;PPP3CB;...
Steroid biosynthesis	-1.82	1.41e-2	19/20 (95%)	DHCR7;SOAT2;LSS;...
Cell adhesion molecules	-1.85	1.18e-2	118/148 (79.73%)	HLA-C;HLA-DOA;ITGAL;...
Th17 cell differentiation	-1.87	9.98e-3	95/107 (88.79%)	TBX21;PLCG1;MAPK3;...
Neutrophil extracellular trap formation	-1.89	9.72e-3	101/189 (53.44%)	PLCG2;CAMP;CR1;...
Osteoclast differentiation	-1.93	5.65e-3	117/127 (92.13%)	LILRA5;PLCG2;CAMK4;...
Autoimmune thyroid disease	-1.94	6.06e-3	46/53 (86.79%)	HLA-C;HLA-DOA;HLA-DMB;...
Herpes simplex virus 1 infection	-1.96	5.44e-3	165/498 (33.13%)	IFNG;OAS3;JAK2;...
Tuberculosis	-2.00	4.71e-3	159/180 (88.33%)	TRADD;MAPK3;TGFB1;...
Phagosome	-2.00	3.86e-3	118/152 (77.63%)	THBS1;ATP6V1C1;STX12;...
Viral myocarditis	-2.06	0.00e+0	53/60 (88.33%)	BID;HLA-C;HLA-DOA;...
Allograft rejection	-2.07	0.00e+0	32/38 (84.21%)	IFNG;HLA-DRA;TNF;...
Graft-versus-host disease	-2.09	0.00e+0	32/42 (76.19%)	IFNG;HLA-DRA;TNF;...
Antigen processing and presentation	-2.11	0.00e+0	60/78 (76.92%)	CD4;HLA-DRA;IFI30;...
Th1 and Th2 cell differentiation	-2.13	0.00e+0	80/92 (86.96%)	JAG2;IL2RB;NOTCH2;...
Platelet activation	-2.13	0.00e+0	106/124 (85.48%)	PLCG2;PLCB2;TLN2;...
Staphylococcus aureus infection	-2.14	0.00e+0	72/95 (75.79%)	HLA-DRA;DEFA4;PTAFR;...
Leishmaniasis	-2.16	0.00e+0	67/77 (87.01%)	MAPK3;TGFB1;ITGB1;...
Lysosome	-2.17	0.00e+0	115/128 (89.84%)	CD164;ASAH1;AP1B1;...
Type I diabetes mellitus	-2.35	0.00e+0	38/43 (88.37%)	HSPD1;GZMB;PTPRN2;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H

MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	6.66uM	72H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 2.22uM	24H

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H

VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H